Nkarta Past Earnings Performance
Past criteria checks 0/6
Nkarta's earnings have been declining at an average annual rate of -26.8%, while the Biotechs industry saw earnings growing at 12.7% annually. Revenues have been declining at an average rate of 149.1% per year.
Key information
-26.8%
Earnings growth rate
45.4%
EPS growth rate
| Biotechs Industry Growth | 17.0% |
| Revenue growth rate | -149.1% |
| Return on equity | -43.0% |
| Net Margin | n/a |
| Last Earnings Update | 31 Dec 2023 |
Recent past performance updates
Recent updates
Nkarta: NK Cell Therapy Advancement On Two Fronts
Mar 25Nkarta: Possible Upside From H1 Update, If Positive
Jan 25Here's Why We're Watching Nkarta's (NASDAQ:NKTX) Cash Burn Situation
Jan 16
We're Keeping An Eye On Nkarta's (NASDAQ:NKTX) Cash Burn Rate
Oct 04We Think Nkarta (NASDAQ:NKTX) Can Afford To Drive Business Growth
Jun 21We Think Nkarta (NASDAQ:NKTX) Can Afford To Drive Business Growth
Mar 06Here's Why We're Not Too Worried About Nkarta's (NASDAQ:NKTX) Cash Burn Situation
Nov 20Nkarta GAAP EPS of -$0.61
Aug 11We're Not Very Worried About Nkarta's (NASDAQ:NKTX) Cash Burn Rate
Jun 09Nkarta: A Promising Natural Killer Cell Play
May 20We Think Nkarta (NASDAQ:NKTX) Can Afford To Drive Business Growth
Aug 23Nkarta (NASDAQ:NKTX) Is In A Good Position To Deliver On Growth Plans
May 10Nkarta gets greenlight from the FDA for NKX019 cancer study
Apr 28We're Not Very Worried About Nkarta's (NASDAQ:NKTX) Cash Burn Rate
Jan 25
Revenue & Expenses BreakdownBeta
How Nkarta makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Dec 23 | 0 | -118 | 30 | 97 |
| 30 Sep 23 | 0 | -122 | 35 | 100 |
| 30 Jun 23 | 0 | -125 | 35 | 102 |
| 31 Mar 23 | 0 | -119 | 30 | 97 |
| 31 Dec 22 | 0 | -114 | 28 | 91 |
| 30 Sep 22 | 0 | -104 | 26 | 81 |
| 30 Jun 22 | 0 | -98 | 24 | 75 |
| 31 Mar 22 | 0 | -93 | 24 | 69 |
| 31 Dec 21 | 0 | -86 | 23 | 63 |
| 30 Sep 21 | 0 | -81 | 24 | 57 |
| 30 Jun 21 | 0 | -72 | 22 | 66 |
| 31 Mar 21 | 0 | -102 | 19 | 42 |
| 31 Dec 20 | 0 | -91 | 15 | 36 |
| 30 Sep 20 | 0 | -84 | 11 | 25 |
| 30 Jun 20 | 0 | -73 | 8 | 0 |
| 31 Mar 20 | 0 | -27 | 6 | 7 |
| 31 Dec 19 | 0 | -21 | 5 | 0 |
| 31 Dec 18 | 7 | 0 | 3 | 0 |
Quality Earnings: NKTX is currently unprofitable.
Growing Profit Margin: NKTX is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: NKTX is unprofitable, and losses have increased over the past 5 years at a rate of 26.8% per year.
Accelerating Growth: Unable to compare NKTX's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: NKTX is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-8.9%).
Return on Equity
High ROE: NKTX has a negative Return on Equity (-43%), as it is currently unprofitable.